USOO9708371B2 (12) United States Patent (10) Patent No.: US 9,708.371 B2 Kessler et al. (45) Date of Patent: Jul.18, 2017 (54) TREATMENTS FOR GASTROINTESTINAL 5,654,278 A 8/1997 Sorensen DSORDERS 5,904,935 A 5/1999 Eckenhoff et al. 6,068,850 A 5, 2000 Stevenson et al. 6,124,261 A 9, 2000 Stevenson et al. (75) Inventors: Marco Kessler, Danvers, MA (US); 6,541,606 B2 4/2003 Margolin et al. Angelika Fretzen, Somerville, MA 6,734,162 B2 5/2004 Van Antwerp (US); Hong Zhao, Lexington, MA 6,828.303 B2 12/2004 Kim et al. (US); Robert Solinga, Brookline, MA 36.3% E: 1339. SN. (US); Vladimir Volchenok, Waltham, 7,056,942- - - B2 6/2006 HildesheimOK et al. MA (US) 7,141,254 B2 11/2006 Bhaskaran et al. 7,304,036 B2 * 12/2007 Currie .................. CO7K 14,245 (73) Assignee: Ironwood Pharmaceuticals, Inc., 514,122 Cambridge, MA (US) 7.351,798 B2 4/2008 Margolin et al. 7,371,727 B2 5/2008 Currie et al. (*)c Notice:- r Subject to any disclaimer, the term of this 7,704,9477,494,979 B2 4/20102/2009 Currie et al. patent is extended or adjusted under 35 7,745,409 B2 6/2010 Currie et al. U.S.C. 154(b) by 364 days. (Continued) (21) Appl. No.: 14/239,178 FOREIGN PATENT DOCUMENTS (22) PCT Filed: Aug. 17, 2012 JP 64-009938 1, 1989 JP 2003-2012.56 T 2003 (86). PCT No.: PCT/US2012/051289 (Continued) S 371 (c)(1), (2), (4) Date: Nov. 21, 2014 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2013/025969 Maier et al. Analogues of Human Calcitonin II. Influence of Modifications in Amino Acid Positions 1, 8 and 22 on PCT Pub. Date: Feb. 21, 2013 Hypocalcemic Activity in the Rat. Hormon. Me tab. Res. 7 (1975) 511-5.14. (65) Prior Publication Data Armed, Hashim and Shah, Navnit., "Formulations of Low Dose Medicines—Theory and Practice.” American Pharmaceutical US 2015/OO9.4272 A1 Apr. 2. 2015 Review, 3(3): 1-4, 2000. Andresen et al., “Effect of 5 days of linaclotide on transit and bowel O O function in females with constipation-predominant irritable bowel Related U.S. Application Data syndrome.” Gastroenterology, 133(3):761-768, 2007. (60) Provisional application No. 61/524.699, filed on Aug. Assis, Linaclotide Acetate.” Drugs of the Future, 33(7): 17, 2011. Angelastro et al., “An efficient synthesis of novel alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and (51) Int. Cl. peptides.” The Journal of Organic Chemistry, 54(16):3913-6, 1989. C07K 7/08 (2006.01) Aventis Pharmaceuticals, Inc. (2002). DDAVP (desmopressin CLID 3/34 (2006.01) acetate) tablet, Product Label). Bridgewater, NJ 08807, USA. C07K 7/54 (2006.01) (Continued) C07K 5/02 (2006.01) Primary Examiner — Satyanarayana R. Gudibande A6 IK 38/10 (2006.01) Assistant Examiner — Jia-Hai Lee A6 IK 38/12 (2006.01) (74) Attorney, Agent, or Firm — Honigman Miller A6 IK 45/06 (2006.01) Schwartz and Cohn LLP. Kelly T. Murphy; Jonathan P. (52) U.S. Cl. O’Brien CPC (2013.01);................ A61KC07K 38/12 7/08 (2013.01); A61K 38/1045/06 (57) ABSTRACT (2013.01); C07K 5/02 (2013.01); C07K 7/54 The present invention features peptides, compositions, and (2013.01): CIID 3/3436 (2013.01); G0IN related methods for treating gastrointestinal disorders and 2800/065 (2013.01) conditions, including but not limited to, irritable bowel (58) Field of Classification Search syndrome (IBS), gastrointestinal motility disorders, func None tional gastrointestinal disorders, gastroesophageal reflux See application file for complete search history. disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional (56) References Cited heartburn, dyspepsia, Visceral pain, gastroparesis, chronic U.S. PATENT DOCUMENTS intestinal pseudo-obstruction (or colonic pseudo-obstruc tion), disorders and conditions associated with constipation, 4,544,568 A 10/1985 Heyland et al. 4,806.524. A 2/1989 Kawaguchi and other conditions and disorders are described herein, 4,992,419 A 2/1991 Woog et al. using peptides and other agents that activate the guanylate 5,221,495 A 6, 1993 Cao cyclase C (GC-C) receptor. 5,451.410 A 9, 1995 Milstein 5,593,696 A 1/1997 McNally et al. 28 Claims, 3 Drawing Sheets US 9,708.371 B2 Page 2 (56) References Cited OTHER PUBLICATIONS U.S. PATENT DOCUMENTS Bedul-Addo, F. et al., “Preformulation Development of Recombi nant Pegylated Staphylokinase SY161 Using Statistical Design.” 7,767,644 B2 8, 2010 Schumann et al. 7,772,188 B2 8, 2010 Currie et al. AAPS PharmSci (http://www.aapspharmsci.org), 4(4) article 19, 7.910,546 B2 3, 2011 Currie et al. 1-11, 2002. 8,080,526 B2 * 12/2011 Currie ...................... CO7K7/08 Bedul-Addo, F.K. et al., “Use of Biophysical Characterization in 514,215 Preformulation Development of a Heavy-Chain Fragment of Botu 8, 101,579 B2 1, 2012 Currie et al. linum Serotype B: Evalulation of Suitable Purification Process 8, 110,553 B2 2, 2012 Currie et al. Conditions.” Pharmaceutical Research, 21 (8): 1353-1361, 2004. 8,748,573 B2 * 6/2014 Fretzen ................... 530/327 Busby et al., "Linaclotide, through activation of guanylate cyclase 8,802,628 B2* 8/2014 Fretzen ................ A61K9/1611 514, 20.6 C, acts locally in the gastrointestinal tract to elictly enhanced 8,933,030 B2 1/2015 Fretzen et al. intestinal secretion and transit.” Eur, J. Pharmacol. 649(1-3): 328 2003,0003563 A1 1, 2003 Vinkemeier et al. 335, 2010. 2003, OO691.82 A1 4, 2003 Rinella Camilleri et al., “Challenges to the Therapeutic Pipeline for Irritable 2003, OO73628 A1 4, 2003 Shailubhai et al. Bowel Syndrome: End Points and Regulatory Hurdles.” Gastroen 2003. O104996 A1 6, 2003 Li et al. terology. 135:1877-1891, 2008. 2003/0175230 A1 9, 2003 Dubief Camilleri, “Management of the Irritable Bowel Syndrome” Gastro 2004/0265242 A1 12, 2004 Bartus enterology, 120:652-668, 2001. 2004/0266989 A1 12, 2004 Currie Capasso et al., “Deamidation via Cyclic Imide of Asparaginyl 2005.0020811 A1 1/2005 Currie et al. Peptides: Dependence on Salts, Buffers and Organic Solvents.” 2005, 0080009 A1 4, 2005 Metzner et al. Peptide Research, 4(4): 234-238, 1991. 2006/0258593 A1 11, 2006 Currie et al. Carpenter et al., “Rational Design of Stable Lyophilized Protein 2007/O122354 A1 5/2007 Hastedt et al. Formulations: Some Practical Advice.' Pharmaceutical Research, 2007. O1544.06 A1 7/2007 Moon et al. 14(8): 969-975, 1997. 2007/0202165 A1 8, 2007 Heuer et al. Carson et al., “Effect of Linaclotide on Quality of Life in Adults 2007/0225216 A1* 9, 2007 MerZouk ................ A61K 38/12 With Chronic Constipation: Results From 2 Randomized, Double 514f13.3 Blind, Placebo-Controlled Phase III Trials.” Gastroenterology, 2009/O110729 A1 4, 2009 Giovannone et al. 139(1):E19, 2010. 2009,0253634 A1 10, 2009 Currie et al. Chourasia, M.K. and Jain, S.K., “Pharmaceutical approaches to 2009/0305993 A1 12, 2009 Currie colon targeted drug delivery systems.” J Pharm Pharmaceut Sci 2010.0048489 A1 2, 2010 Fretzen et al. (www.ualberta.ca/-csps), 6(1): 33-66, 2003. 2010O221329 A1 9, 2010 Shailubhai et al. Cleland et al., “The Development of Stable Protein Formulations: A 2012,0009225 A1 1, 2012 Fretzen et al. Close Look at Protein Aggregation, Deamidation, and Oxidation.” 2012/0039949 A1 2, 2012 Fretzen et al. Critical Reviews in Therapeutic Drug Carrier Systems, 10(4): 2012fO213846 A1 8, 2012 Fretzen et al. 307-377, 1993. 2013, OO12454 A1 1, 2013 Mo et al. Constantino, H.R. et al., “Moisture-Induced Aggregation of 2013, O190239 A1 T/2013 Fretzen et al. Lyophilized Insulin’. Pharmaceutical Research, 11(1): 21-29, 1994. 2013/0273.169 A1 10, 2013 Fretzen et al. Cook et al., “Chronic constipation: Overview and Challenges.” Neurogastroenterology and Motility, 21(supp2): 1-8, 2009. FOREIGN PATENT DOCUMENTS Dulbecco et al., “Plaque formation and isolation of pure liner with poliomyelitis viruses.” Journal of Experimental Medicine, 99(2): WO WO9012029 10, 1990 WO WO9104743 4f1991 167-182, 1954. WO WO9703692 2, 1997 Elan Pharmaceuticals, Inc. (2004). PRIALT (Ziconotide) injection, WO WO9704796 2, 1997 solution, Product Label. San Diego, CA 92121, USA. WO WO98OO152 1, 1998 Fix, J.A., “Oral Controlled Release Technology for Peptides: Status WO WO98OO157 1, 1998 and Future Prospects.” Pharmaceutical Research, 13(12): 1760 WO WOOOO488O 2, 2000 1764, 1996. WO WOOO32172 6, 2000 Forest, “Phase III randomized double-blind placebo-controlled trial WO WOO226248 4/2002 of linaclotide administered to patients with chronic constipation.” WO WOO2O78683 10, 2002 2008. Retrieved from <<http:www.clinicaltrials.gov) identifier WO WOO3.014304 2, 2003 NCT00765882 on Dec. 9, 2010. WO WOO3055511 T 2003 Fu et al., “Protein Stability in Controlled-Release Systems.” Nature WO WOO2O62369 8, 2003 Biotechnology, 18: 24-25, 2000. WO WO2004.052343 6, 2004 WO WO2004O69165 8, 2004 Grenha et al., "Chitosan nanoparticles are compatible with respi WO WO2004 108152 12, 2004 ratory epithelial cells in vitro.” European Journal of Pharmaceutical WO WO2005O14025 2, 2005 Sciences, 31: 73-84, 2007. WO WO2005042O29 5, 2005 Harris et al., “Drug evaluation: Linaclotide, a new direction in the WO WO2005087797 9, 2005 treatment of irritable bowel syndrome and chronic constipation.” WO WO2007022531 2, 2007 Current Opinion in Molecular Therapeutics, 9(4):403-410, 2007. WO WO2007044375 4/2007 Harris, “Constipation: Linaclotide—a stimulating new drug for WO WO2O08006125 1, 2008 chronic constipation.” Nature Reviews Gastroenterology and WO WO2O0802.1133 2, 2008 Hepatology, 7(7):365-6, 2010. WO WO2O08027854 3, 2008 “International Nonproprietary Names for Pharmaceutical Sub WO WO2O08078189 T 2008 stances (INN).” WHO Drug Information, 21(3): 247-264, 2007.